@article{10.11648/j.ijde.20251002.12,
  author = {Jannatul Ferdous and Muhammad Mobarock Hossain and Mst Jakanta Faika and Monowara Begum and Samira Mahjabeen and Iffat Ara Jahan and Mahira Zehreen Khan and Moktadir Mobarock Monsur Hossain},
  title = {Role of Tirzepatide in Obesity Management Among Women with Polycystic Ovary Syndrome
},
  journal = {International Journal of Diabetes and Endocrinology},
  volume = {10},
  number = {2},
  pages = {37-44},
  doi = {10.11648/j.ijde.20251002.12},
  url = {https://doi.org/10.11648/j.ijde.20251002.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20251002.12},
  abstract = {Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women, often associated with obesity, insulin resistance, and metabolic complications. Managing weight is crucial for improving PCOS symptoms and overall health. This study aimed to evaluate the effectiveness of Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, in obesity management and symptom improvement among women with PCOS. Methods: This retrospective observational study was conducted in the Department of Cardiology, Uttara Adhunik Medical College Hospital, LabAid Cancer Hospital & Super Speciality Centre, LabAid Diagnostics Center, Uttara, Dhaka, Bangladesh, from July 2024 to February 2025. In this study, we included 56 women with polycystic ovary syndrome associated with obesity who were referred to a consultant gynecologist or cardiologist for menstrual problems, obesity, and hypertension. Result: In this study, we found that after treatment, there was a significant weight reduction of 9.54% (p = 0.0004), with BMI decreasing from 36.51 ± 6.14 to 32.49 ± 4.68 kg/m² (p = 0.0002). Glycemic control improved significantly, with fasting blood sugar dropping from 6.89 ± 0.78 mg/dl to 5.57 ± 0.42 mg/dl (p < 0.0001) and HbA1c decreased from 5.7 ± 0.6% to 4.9 ± 0.4% (p < 0.0001). PCOS symptoms showed remarkable improvement, with irregular menstrual cycles decreased from 85.7% to 32.1% (p < 0.0001), and ovarian cyst prevalence dropped from 89.3% to 41% (p < 0.0001). Insulin resistance improved significantly (80.4% to 50%, p = 0.0008). The most common side effects were heartburn (42.86%), nausea/vomiting (39.29%), and general weakness (33.93%). Conclusion: In this study, Tirzepatide showed promising results in managing obesity and improving metabolic outcomes in women with PCOS. Significant weight reduction, glycemic control, and symptom improvement were observed in our study patients. Our study suggests that Tirzepatide could be a valuable therapeutic option for obese women with PCOS.
},
 year = {2025}
}

Copy | Download

TY  - JOUR
T1  - Role of Tirzepatide in Obesity Management Among Women with Polycystic Ovary Syndrome

AU  - Jannatul Ferdous
AU  - Muhammad Mobarock Hossain
AU  - Mst Jakanta Faika
AU  - Monowara Begum
AU  - Samira Mahjabeen
AU  - Iffat Ara Jahan
AU  - Mahira Zehreen Khan
AU  - Moktadir Mobarock Monsur Hossain
Y1  - 2025/04/28
PY  - 2025
N1  - https://doi.org/10.11648/j.ijde.20251002.12
DO  - 10.11648/j.ijde.20251002.12
T2  - International Journal of Diabetes and Endocrinology
JF  - International Journal of Diabetes and Endocrinology
JO  - International Journal of Diabetes and Endocrinology
SP  - 37
EP  - 44
PB  - Science Publishing Group
SN  - 2640-1371
UR  - https://doi.org/10.11648/j.ijde.20251002.12
AB  - Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women, often associated with obesity, insulin resistance, and metabolic complications. Managing weight is crucial for improving PCOS symptoms and overall health. This study aimed to evaluate the effectiveness of Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, in obesity management and symptom improvement among women with PCOS. Methods: This retrospective observational study was conducted in the Department of Cardiology, Uttara Adhunik Medical College Hospital, LabAid Cancer Hospital & Super Speciality Centre, LabAid Diagnostics Center, Uttara, Dhaka, Bangladesh, from July 2024 to February 2025. In this study, we included 56 women with polycystic ovary syndrome associated with obesity who were referred to a consultant gynecologist or cardiologist for menstrual problems, obesity, and hypertension. Result: In this study, we found that after treatment, there was a significant weight reduction of 9.54% (p = 0.0004), with BMI decreasing from 36.51 ± 6.14 to 32.49 ± 4.68 kg/m² (p = 0.0002). Glycemic control improved significantly, with fasting blood sugar dropping from 6.89 ± 0.78 mg/dl to 5.57 ± 0.42 mg/dl (p < 0.0001) and HbA1c decreased from 5.7 ± 0.6% to 4.9 ± 0.4% (p < 0.0001). PCOS symptoms showed remarkable improvement, with irregular menstrual cycles decreased from 85.7% to 32.1% (p < 0.0001), and ovarian cyst prevalence dropped from 89.3% to 41% (p < 0.0001). Insulin resistance improved significantly (80.4% to 50%, p = 0.0008). The most common side effects were heartburn (42.86%), nausea/vomiting (39.29%), and general weakness (33.93%). Conclusion: In this study, Tirzepatide showed promising results in managing obesity and improving metabolic outcomes in women with PCOS. Significant weight reduction, glycemic control, and symptom improvement were observed in our study patients. Our study suggests that Tirzepatide could be a valuable therapeutic option for obese women with PCOS.

VL  - 10
IS  - 2
ER  - 

Copy | Download